ycopene nephroprotective effect in patients receiving vancomyci

Phase 3

Recruiting

• Conditions: Vancomycin-induced nephrotoxicity.; Toxic nephropathy, not elsewhere classified; N14.4

• Registration Number: IRCT20171030037093N37
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Serum creatinine levels less than 1.2 mg / dl at the start of the study
Creatinine clearance (ClCr)> 90 ml / min upon admission
Lack of underlying renal impairment such as glomerulonephritis, polycystic kidney disease, kidney stones, interstitial nephritis, renal artery stenosis and renal carcinoma
Lack of underlying diseases causes kidney disorders such as diabetes mellitus and high blood pressure
Hospital history and failure to receive other nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, tacrolimus and furosemide, etc.
Do not take other antioxidant supplements such as vitamins C and E.

Exclusion Criteria

History of acute kidney damage
Lycopene allergy history
History of injectable addiction

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum creatinine. Timepoint: Before starting treatment, one day between treatments and 12 hours after the last dose of vancomycin on the tenth day of treatment. Method of measurement: Photometric.;Blood urea nitrogen. Timepoint: Before starting treatment, one day between treatments and 12 hours after the last dose of vancomycin on the tenth day of treatment. Method of measurement: Photometric.;Creatinine clearance. Timepoint: Before starting treatment, one day between treatments and 12 hours after the last dose of vancomycin on the tenth day of treatment. Method of measurement: Cockcroft-Gault formula.